RxDoctor Payments Data

Amir Latifi-M-Tehrani, MD

Infectious Disease · Stony Brook, NYNPI 1972791150

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $26,425 of the $27,660 with a category attached, or 95.5%. Shionogi Inc accounts for 99.6% of it on its own, with 1 other manufacturer making up the rest. 2025 is the largest year on record at $9,778, more than ten times the $119 reported in 2019. Among infectious disease clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$27,660in general payments, 2019–2025

Across 26 payments — averaging $1063.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shionogi Inc$28K
  • Gilead$119

What the payments were for

  • Speaking & faculty fees$26,42596%
  • Food & beverage$1,2234%
  • Education$130%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Shionogi Inc25$27,541
Gilead1$119

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,660 in reported general payments places this provider in the 90th percentile of 799 infectious disease providers in New York.

See all infectious disease providers in New York →

Medicare billing

Part B allowed, 2024
$474,576
Medicare patients
380
Services billed
4,410

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other infectious disease in Stony Brook

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →